Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: Randomized comparison of fenofibrate 160mg and niacin 1500mg

Atherosclerosis

Volumn 213, Issue 1, 2010, Pages 235-240

  Wi, Jin ^a   Kim, Jong Youn ^a   Park, Sungha ^a   Kang, Seok Min ^a   Jang, Yangsoo ^a   Chung, Namsik ^a   Shim, Won Heum ^a   Cho, Seung Yun ^a   Lee, Sang Hak ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Apolipoprotein A1; Apolipoprotein B; Dyslipidemias; Fibric acid; Glucose; Inflammation; Niacin

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; EXLIP; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTHRALGIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDEMA; FEMALE; FEVER; FLUSHING; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INFLAMMATION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN SENSATION; SUSTAINED RELEASE FORMULATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; URINARY FREQUENCY; WEAKNESS;

ADULT; AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; CHOLESTEROL, HDL; FEMALE; FENOFIBRATE; FIBRIC ACIDS; GLUCOSE; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; INFLAMMATION; MALE; MIDDLE AGED; NIACIN;

EID: 77958453238     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.08.068     Document Type: Article

References (25)

1. Ford E.S., Li C., Zhao G., Pearson W.S., Mokdad A.H. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med 2009, 169:572-578.
2. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
3. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
4. Rosenson R.S., Helenowski I.B., Woliff D.A., Rademaker A.W., Huskin A.L. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care 2007, 30:1945-1951.
5. Franceschini G., Calabresi L., Colombo C., Favari E., Bernini F., Sirtori C.R. Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients. Atherosclerosis 2007, 195:385-391.
6. Goldberg A., Alagona P., Capuzzi D.M., et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 2000, 85:1100-1105.
7. Athyros V.G., Demitriadis D.S., Papageorgiou A.A., Kontopoulos A.G., Athyrou V.V. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002, 25:1198-1202.
8. Davidson M.H., Rooney M.W., Drucker J., Griffin H.E., Oosman S., Beckert M. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. Clin Ther 2009, 31:2824-2838.
9. Grundy S.M., Vega G.L., McGovern M.E., et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial. Arch Intern Med 2002, 162:1568-1576.
10. Birjmohun R.S., Hutten B.A., Kastelein J.J., Stores E.S. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005, 45:185-197.
11. Belfort R., Berria R., Cornell J., Cusi K. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab 2010, 95:829-836.
12. Alrasadi K., Awan Z., Alwaili K., et al. Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20mg) versus fenofibrate (200mg) versus extended-release niacin (2g). Am J Cardiol 2008, 102:1341-1347.
13. Carlson L.A., Hamsten A., Asplund A. Pronounced lowering of serum levels of lipoprotein Lp (a) in hyperlipidemic subjects treated with nicotinic acid. J Intern Med 1989, 226:271-276.
14. Fabbrini E., Mohammed B.S., Korenblat K.M., et al. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2010, 95:2727-2735.
15. Elam M.B., Hunninghake D.B., Davis K.B., et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000, 284:1263-1270.
16. Muhlestein J.B., May H.T., Jensen J.R., et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol 2006, 48:396-401.
17. Theones M., Oguchi A., Nagamia S., et al. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome. Int J Clin Pract 2007, 61:1942-1948.
18. Kuvin J.T., Dave D.M., Sliney K.A., et al. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol 2006, 98:743-745.
19. Davidson M.H., Armani A., McKenney J.M., Jacobson T.A. Safety consideration with fibrate therapy. Am J Cardiol 2007, 99:3C-8C.
20. Keating G.M., Croom K.F. Fenofibrate: a review of its use in primary dyslipidemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs 2007, 67:121-153.
21. Jacobson T.A. A "hot" topic in dyslipidemia management-" How to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention. Mayo Clin Proc 2010, 85:365-379.
22. Canner P.L., Berge K.G., Wenger N.K., et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986, 8:1245-1255.
23. Taylor A.J., Villines T.C., Stanek E.J., et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009, 361:2113-2122.
24. Al-Mohaissen M.A., Pun S.C., Frolich J.J. Niacin: from mechanisms of action to therapeutic uses. Mini Rev Med Chem 2010, 10:204-217.
25. Chapman M.J., Redfern J.S., McGovern M.E., Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther. 2010, 126:314-345.